Similarly, anti-tumor effect generated through activation of TLR2 and 4, by OM-174 (CXR-526), a lipid A (Escherichia coli origin) derivative, is currently being evaluated as a vaccine adjuvant for the treatment of melanoma in phase I/II trials, in addition to a phase I trial against solid tumors (152). Here, TLR2 is linked to neoplasm.